• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Invest . An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer

tetano

Editor, Senior Moderator
J Clin Invest


. 2022 Apr 26;e159062.
doi: 10.1172/JCI159062. Online ahead of print.
An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer


Naveenchandra Suryadevara[SUP] 1 [/SUP], Andrea R Shiakolas[SUP] 2 [/SUP], Laura A VanBlargan[SUP] 3 [/SUP], Elad Binshtein[SUP] 1 [/SUP], Rita E Chen[SUP] 3 [/SUP], James Brett Case[SUP] 3 [/SUP], Kevin J Kramer[SUP] 2 [/SUP], Erica C Armstrong[SUP] 1 [/SUP], Luke Myers[SUP] 1 [/SUP], Andrew Trivette[SUP] 1 [/SUP], Christopher Gainza[SUP] 1 [/SUP], Rachel S Nargi[SUP] 1 [/SUP], Christopher N Selverian[SUP] 4 [/SUP], Edgar Davidson[SUP] 5 [/SUP], Benjamin J Doranz[SUP] 6 [/SUP], Summer M Diaz[SUP] 1 [/SUP], Laura S Handal[SUP] 1 [/SUP], Robert H Carnahan[SUP] 7 [/SUP], Michael S Diamond[SUP] 3 [/SUP], Ivelin S Georgiev[SUP] 1 [/SUP], James E Crowe Jr[SUP] 1 [/SUP]



Affiliations

Abstract

The protective human antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus focuses on the spike (S) protein which decorates the virion surface and mediates cell binding and entry. Most SARS-CoV-2 protective antibodies target the receptor-binding domain or a single dominant epitope ('supersite') on the N terminal domain (NTD). Here, using the single B cell technology LIBRA-seq, we isolated a large panel of NTD-reactive and SARS-CoV-2 neutralizing antibodies from an individual who had recovered from COVID-19. We found that neutralizing antibodies to the NTD supersite commonly are encoded by the IGHV1-24 gene, forming a genetic cluster that represents a public B cell clonotype. However, we also discovered a rare human antibody, COV2-3434, that recognizes a site of vulnerability on the SARS-CoV-2 S protein in the trimer interface and possesses a distinct class of functional activity. COV2-3434 disrupted the integrity of S protein trimers, inhibited cell-to-cell spread of virus in culture, and conferred protection in human ACE2 transgenic mice against SARS-CoV-2 challenge. This study provides insight about antibody targeting of the S protein trimer interface region, suggesting this region may be a site of virus vulnerability.

Keywords: Adaptive immunity; Antigen; Immunoglobulins; Immunology; Virology.
 
Back
Top Bottom